logo
Liver specialist explains how hepatitis affects women; tips and tests every woman should know for early detection

Liver specialist explains how hepatitis affects women; tips and tests every woman should know for early detection

Hindustan Times29-07-2025
The World Health Organisation (WHO) has defined hepatitis as an inflammation of the liver that is caused by a variety of infectious viruses and non-infectious agents, leading to a range of health problems, including severe liver damage and cancer, some of which can be fatal. There are 5 main strains of the hepatitis virus, referred to as types A, B, C, D and E. Many women are unaware of how Hepatitis B spreads—via blood, unsafe sex, or from mother to child—often mistaking it for a lifestyle-related or liver-specific issue alone. (Shutterstock)
Also Read | Gastroenterologist lists 8 groups of people who are at higher risk; shares when to get tested
WHO data says that types B and C lead to chronic disease in hundreds of millions of people, and an estimated 1.3 million deaths per year. According to the World Hepatitis Alliance, globally, women face more challenges in accessing quality health services due to sociocultural and economic factors and discrimination. Therefore, it becomes necessary to educate them about this disease.
Hepatitis and the problems faced by women
In an interview with HT Lifestyle, Dr Jignesh Patel, gastroenterologist and liver specialist, HCG Hospitals, Ahmedabad, stressed that hepatitis B remains a serious yet preventable public health issue in India. While women form the backbone of families and communities, their awareness and protection against Hepatitis B often remain inadequate. The gap is not just in healthcare access, but in education, screening, and social perception.
Without targeted screening, many individuals - especially women - do not realise that they are infected until the disease has progressed and caused serious liver damage. (Freepik)
According to Dr Vikram Vora, medical director, International SOS (India), hepatitis infections, especially hepatitis B and C, can remain asymptomatic for years. He stressed, 'Without targeted screening, many individuals - especially women juggling multiple roles, who are unable to focus on their own health and wellbeing - do not realise that they are infected until the disease has progressed and caused serious liver damage, including fibrosis, cirrhosis or hepatocellular carcinoma.'
'This culturally ingrained self-neglect means symptoms, when they appear, may be brushed aside or misattributed to stress or hormonal changes. In working women, this can be even more pronounced due to the complex interplay of occupational, social, and biological factors,' he added.
What stops early detection in women
1. Lack of Awareness
'Many women are unaware of how Hepatitis B spreads—via blood, unsafe sex, or from mother to child. It is often mistaken for a lifestyle-related or liver-specific issue alone,' Dr Patel explained.
'Working women often operate under significant time pressure, regardless of whether they work in formal or informal sectors. Between managing household responsibilities and professional demands, preventive health checkups end up being deprioritised. Although corporate wellness programs have started to focus on non-communicable diseases (like diabetes and hypertension), rarely do they include hepatitis screening,' Dr Vora added.
2. Inadequate Screening
Per Dr Patel, a simple blood test, S. HBsAg, is enough to screen for Hepatitis B. 'This test should be strongly recommended for all women, especially before pregnancy, to detect infection early and prevent transmission to the child,' he said.
However, clinics often operate during standard working hours, and relatively few employers offer on-site testing or flexible leave for preventive health services. 'This creates a vicious cycle of low awareness, low testing and consequently, late diagnosis,' Dr Vora explained.
3. Vaccination Gaps
'While childhood vaccination is part of India's Universal Immunisation Program, adult women—particularly in reproductive age—often miss out on catch-up vaccination, putting them at avoidable risk,' Dr Patel explained.
Dr Vora added, 'Despite the availability of effective hepatitis B vaccines and curative treatments for hepatitis C, awareness remains low. Many women are unaware of their vaccination status or the need for screening, especially if they were born before hepatitis B vaccination was included in national immunisation programs.'
Tattoos can be a hidden threat if done at unlicensed parlours with non-sterile equipment. (Freepik)
4. Unsafe Practices:
Hepatitis is also compounded by social stigma, largely due to its association with sexual transmission or drug use, Dr Vora emphasised. 'Even educated women may feel hesitant to seek testing or disclose their status for fear of being misunderstood, judged, or discriminated against in the workplace,' he explained.
Therefore, safe sex practices must be emphasised, especially among young adults, per Dr Patel. 'Tattoos, which are increasingly popular among younger women as a form of self-expression, can be a hidden threat if done at unlicensed parlours with non-sterile equipment. Tattooing with contaminated needles is a known route for Hepatitis B transmission,' he added.
5. Stigma and Silence:
Dr Patel explained, 'There is a hesitation to undergo screening or discuss Hepatitis B openly due to the associated stigma. This social silence delays diagnosis and care.'
Tips and tests women should know about early detection
Here are some key things to remember, as per Dr Patel:
Routine Hepatitis B screening (S. HBsAg)should be made a standard part of pre-marital and pre-pregnancy health checks. Promote vaccination for all unvaccinated women as part of preventive health campaigns. Educate women on transmission routes and the importance of safe sex and safe body art practices. Conduct awareness drives in schools, colleges, and workplaces to normalise conversations around liver health and Hepatitis B. Providenon-judgmental clinical environments where women feel safe to seek testing and treatment.
Workplace awareness
Lastly, Dr Vora highlighted how hepatitis education is often absent from workplace wellness communications. 'Without targeted information campaigns, the average working woman remains unaware of the long-term risks of chronic hepatitis or the ease of getting screened with a simple blood test,' he stated.
To bridge this gap, Dr Vora suggested a need for comprehensive and gender-sensitive workplace health and wellness policies:
Awareness: Constant availability of health information from credible and medically validated sources. Screening and Education: Ensuring workplace testing or the provision of access to external screening. Destigmatization: An open culture where discussions around health conditions are free and frank without prejudice Engagement: Using digital enablement and fostering a sense of community.
Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

WHO calls for research scale-up towards ending TB in South-East Asia region
WHO calls for research scale-up towards ending TB in South-East Asia region

News18

time6 hours ago

  • News18

WHO calls for research scale-up towards ending TB in South-East Asia region

New Delhi, Aug 5 (PTI) The WHO on Tuesday called for urgent scale-up of research, innovation and collaboration to accelerate momentum towards ending tuberculosis in the South-East Asia region, which continues to bear nearly half of the global TB burden, accounting for the highest share of cases and deaths worldwide. Experts, national TB programme managers and researchers along with partners and members of civil society began a three-day virtual workshop organised by the World Health Organization (WHO) for advancing research and innovation to accelerate momentum towards ending TB in the WHO South-East Asia region. 'In our Region alone, nearly 5 million people developed TB and close to 600,000 died from the disease in 2023," said Dr Catharina Boehme, Officer-in-Charge, WHO South-East Asia Region. Calling for urgent action, she said that achieving the ambitious targets in the WHO End TB Strategy requires collaboration to accelerate research and innovation. It requires the adoption and use of new tools, technologies and drugs. Ensuring timely and equitable access to these innovations remains critical to achieving impacts at scale, leaving no one behind, Boehme said. While the region recorded a significant increase in TB case notifications in 2023, signalling recovery after COVID-19-related setbacks, progress remains insufficient to meet the End TB Strategy targets aligned with the sustainable development goals that call for a 90 per cent reduction in TB deaths and an 80 per cent reduction in incidence by 2030 compared to 2015 levels. Post-COVID-19 pandemic, TB once again reemerged as the world's leading cause of death from a single infectious agent, the WHO said in a statement. It places a disproportionate burden on the poorest and most vulnerable, further exacerbating inequalities. In the South-East Asia region, 30 per cent to 80 per cent of the TB-affected households experience catastrophic costs, underscoring the need for equitable, people-centred approaches and strengthening social protection for the affected, the statement said. Despite these challenges, the WHO South-East Asia region made notable progress. In 2023, 3.8 million new and relapse TB cases were notified, with an 89 per cent treatment success rate for those who began treatment in 2022. Missed cases dropped to 22 per cent in 2023, down from 44 per cent in 2020, the statement said. Backed by strong political commitment, countries in the region are increasingly leveraging new approaches such as artificial intelligence for case detection, computer-aided diagnostics, digital adherence tools and direct benefit transfers for patients, streamlining the social support process. At the same time, several countries are undertaking important research, including epidemiological research to assess the disease burden, the statement said. Bangladesh recently completed a patient cost survey, while findings from India's RATIONS study on the impact of nutrition on TB outcomes and incidence of the disease have contributed to the global guidance. Social and community-based innovations are also playing a vital role. Nepal's TB-Free Pallika initiative and multisectoral coordination mechanisms in Myanmar are helping reach vulnerable populations with person-centred care. A review by the WHO South-East Asia found that member states published over 3,000 TB-related research articles in the past six years, with 60 per cent being original research. However, uptake of research outcomes remains uneven due to knowledge gaps and limited platforms for knowledge exchange and collaborative use, the statement said. 'Our progress is uneven. Research and innovation capacity is varied across the Region, and the results of these efforts are often siloed and unavailable for collaborative use. The rise in drug-resistant forms of TB remains very concerning," said Dr Boehme. The key areas of focus during the virtual consultation include strengthening of South-South collaboration, vaccine preparedness, digital tools for patient care and adherence and efforts to overcome vaccine hesitancy. Participants will also discuss aligning regulatory processes, promoting data sharing and improving platforms for knowledge exchange. A significant emphasis is being placed on identifying operational implementation research priorities, especially in relation to social determinants such as undernutrition and climate change, which influence TB incidence and outcomes. top videos View all 'Several ongoing innovations are attempting to reach out to marginalized and vulnerable groups through active case finding and providing affected families socio-economic support to mitigate catastrophic costs", said Dr Boehme. Highlighting the importance of equity, she added, 'It is incumbent to ensure equitable access to the benefits of research and innovation, including vaccines, medicines and diagnostics." PTI PLB KSS KSS (This story has not been edited by News18 staff and is published from a syndicated news agency feed - PTI) view comments First Published: August 05, 2025, 19:30 IST News agency-feeds WHO calls for research scale-up towards ending TB in South-East Asia region Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

Early immunisation critical in preventing RSV in infants
Early immunisation critical in preventing RSV in infants

Hindustan Times

time6 hours ago

  • Hindustan Times

Early immunisation critical in preventing RSV in infants

Respiratory illnesses in newborns are a major cause of concern, especially when they involve difficulty in breathing. Among the leading causes is Respiratory Syncytial Virus (RSV), a common and highly severe virus that affects the lungs and airways of infants and children under five. This virus often mimics symptoms of a common cold, such as a runny nose or low-grade fever. This similarity can create confusion for parents and health care providers alike, leading to delays in detection and intervention, which allows the illness to rapidly escalate. Vaccination (Getty Images/iStockphoto) For newborns and infants, whose immune systems are still developing, and airways are small, RSV can quickly become serious. Their tiny airways can get easily blocked by swelling and mucus, leading to lung infections like bronchiolitis or pneumonia. Each year, RSV leads to over 3.6 million hospitalisations and about 100 000 deaths in children under five years of age. As per WHO, most paediatric RSV deaths (97%) occur in low- and middle-income countries where there is limited access to supportive medical care. Even healthy, full-term babies can face complications, and in some cases, require intensive medical care. In India, RSV cases spike during the monsoon and early winter, but the virus can circulate throughout the year. This makes timely protection critical. Medical advancements now offer a way to shield infants through immunisation strategies. While the RSVpreF maternal vaccine is not yet available in India, two monoclonal antibodies have emerged as key preventive options in India. Palivizumab, is administered monthly to high-risk infants such as those born prematurely or with underlying heart or lung conditions. Nirsevimab, on the other hand, is a long-acting monoclonal antibody offering protection with a single-dose. It is designed for all infants regardless of risk category and can be administered soon after birth, before hospital discharge, or during early routine check-ups. Early immunization plays a vital role in protecting infants not just from immediate illness, but also from long-term respiratory complications. Severe RSV infections in the first year of life have been linked to increased risk of recurrent wheezing, asthma, ear infections, and reduced lung function well into adolescence. Infants are especially vulnerable because their immune systems are still developing, and their smaller airways are more easily blocked by inflammation caused by the virus. By providing protection before exposure, through timely use of preventive monoclonal antibodies, we are better equipped to avoid serious outcomes for babies. Parents must understand the importance of stopping the virus before it can take hold, reducing the likelihood of hospitalisation and long-term health issues. For parents and health care providers alike, early immunisation isn't just a seasonal precaution, it's a critical investment in the child's long-term respiratory health and overall well-being. This article is authored by Dr Faisal B Nahdi, paediatrician, Rainbow Children's Hospital, Hyderabad.

What are chikungunya symptoms? CDC issues travel warning for China amid outbreak
What are chikungunya symptoms? CDC issues travel warning for China amid outbreak

Hindustan Times

time6 hours ago

  • Hindustan Times

What are chikungunya symptoms? CDC issues travel warning for China amid outbreak

Americans travelling to China have been advised to practice utmost caution in the wake of the chikungunya virus outbreak in the country. A Level 2 travel alert was issued by the US Centers for Disease Control and Prevention (CDC) in this regard last week. CDC issued warning for Americans traveling to China after the Chikungunya outbreak.(Unsplash) This comes as more than 7,000 cases of the mosquito-borne virus were reported in the Guangdong province of China, forcing the authorities to put in measures similar to the ones taken during the COVID-19 pandemic period, as per BBC. Among the worst-affected regions in the country is the city of Foshan, where chikungunya patients have been ordered to stay in the hospital until they test negative. They will be discharged at the end of a week-long stay, and their beds are being protected using mosquito nets. Chikungunya: What to know? The viral disease is transmitted mainly through the Aedes mosquitoes. It is caused by the chikungunya virus (CHIKV), which is an RNA virus in the alphavirus genus of the Togaviridae family, as per the World Health Organization (WHO). CHIKV was identified for the first time in the United Republic of Tanzania in 1952, while major outbreaks have been reported in America, Asia, and Africa. A study that came out in Nature in June this year, estimated that around 35.3 million people get infected by Chikungunya on an annual basis across 180 countries and regions. It leads to nearly 3,700 deaths, which is 0.01% of the total cases, as per TIME magazine. The latest outbreak in China has been attributed to imported cases. Liu Qiyong, China CDC's chief expert in vector-borne disease control, told CGTN, 'With the virus spreading globally, imported cases have inevitably reached China.' Chikungunya symptoms The WHO states that chikungunya symptoms are quite similar to dengue and Zika, thus making it difficult to diagnose the disease and accurately determine the total number of infected persons. Also read: Chikungunya outbreak: China on high alert as Guangdong battles over 7,000 cases amid COVID like strict measures Some of the most common symptoms of Chikungunya include high fever, joint pain, headache, muscle pain, as well as joint swelling and rashes. The symptoms usually appear around 4-8 days after the patient is bitten by the infected mosquito. At first, the person gets to witness an 'abrupt onset of fever, frequently accompanied by severe joint pain,' as per the WHO. Notably, the joint pain is often debilitating and can last anywhere from a few days to weeks, months, and even years in some cases. While most of the patients completely recover from the infection, there are cases of eye, heart, and neurological complications that have come up due to the CHIKV infection. FAQs: 1. Why CDC has issued a warning for China? CDC's Level 2 alert, which is designated as 'Practice Enhanced Precautions', came out after China marked over 7,000 cases of chikungunya infections. 2. How are chikungunya patients treated? No specific antiviral treatment is available for the chikungunya virus infections. Usually, doctors give antipyretic and analgesic medications, like paracetamol, for fever and pain, as per the WHO. Also, there are two chikungunya vaccines that have received regulatory approvals, but these are not widely available. 3. Is chikungunya fatal? Severe symptoms and deaths from the viral disease are rare, occurring mostly among young children or elderly people who have co-existing health problems.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store